HDACi could prevent breast tumor progression via transcriptional reduction of EMT, induction of ER in hormone receptor-negative tumors, improving the sensitivity of hormonal therapy in ER + tumor, or modulating the expression of HER2 (Connolly et al., 2017). Here, NR4A1 is linked to breast neoplasm.